Medicare Part D coverage · daridorexant · RxCUI 2599098
daridorexant 50 MG Oral Tablet [Quviviq]
Per the CMS 2026 Part D formulary file, daridorexant 50 MG Oral Tablet [Quviviq] is covered by 960 Medicare Part D plans (19% of enrollable products), averaging Tier 3.5, with prior authorization required on 0% of covering formularies.
- 19%
- Plan coverage
- 960
- Plans covering
- T3.5
- Avg tier
- 0%
- Prior auth required
What the CMS Formulary Data Shows for daridorexant 50 MG Oral Tablet [Quviviq]
Per the CMS 2026 Part D formulary file, daridorexant 50 MG Oral Tablet [Quviviq] (RxNorm concept RXCUI 2599098, generic name daridorexant) appears on 8 distinct formulary files spanning 960 Medicare Part D plan offerings - 19% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 3 to Tier 4, with a cross-plan average of Tier 3.5.
Real-world access to daridorexant 50 MG Oral Tablet [Quviviq] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 10,838 Part D beneficiaries filled daridorexant 50 MG Oral Tablet [Quviviq] in 2023, with total plan-and-beneficiary spending of $16,342,719 and an average per-beneficiary annual cost of $1,507.91. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry daridorexant 50 MG Oral Tablet [Quviviq] today.
Coverage Details
- Formularies covering
- 8
- Plans covering
- 960
- Coverage rate
- 19%
- Tier range
- Tier 3 – Tier 4
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 100% of formularies
2023 Medicare Spending
- Beneficiaries
- 10,838
- Total spending
- $16,342,719
- Avg per beneficiary
- $1,507.91
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering daridorexant 50 MG Oral Tablet [Quviviq]
100 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Wellpoint Medicare Advantage (HMO-POS) | Wellpoint West Virginia , Inc. | T3 | No | $0 | WV |
| Anthem Medicare Advantage 3 (HMO-POS) | Healthkeepers, Inc. | T3 | No | $0 | VA |
| Anthem Medicare Advantage 3 (HMO-POS) | Healthkeepers, Inc. | T3 | No | $0 | VA |
| Anthem Medicare Advantage 3 (HMO-POS) | Healthkeepers, Inc. | T3 | No | $0 | VA |
| Wellpoint Medicare Advantage 2 (HMO-POS) | Wellpoint Tennessee, Inc. | T3 | No | $0 | TN |
| Wellpoint Medicare Advantage 2 (HMO-POS) | Wellpoint Tennessee, Inc. | T3 | No | $0 | TN |
| Wellpoint Medicare Advantage 2 (HMO-POS) | Wellpoint Tennessee, Inc. | T3 | No | $0 | TN |
| Wellpoint Medicare Advantage 2 (HMO-POS) | Wellpoint Tennessee, Inc. | T3 | No | $0 | TN |
| Anthem Medicare Advantage (HMO-POS) | Blue Cross OF California | T3 | No | $0 | CA |
| Anthem Medicare Advantage (HMO-POS) | Blue Cross OF California | T3 | No | $0 | CA |
| Anthem Medicare Advantage (HMO-POS) | Blue Cross OF California | T3 | No | $0 | CA |
| Anthem Medicare Advantage (HMO-POS) | Blue Cross OF California | T3 | No | $0 | CA |
| Anthem Full Dual Advantage (HMO D-SNP) | Anthem Insurance Companies, Inc. | T3 | No | $0 | IN |
| Anthem I PathWays Dual Care Advantage (HMO D-SNP) | Anthem Insurance Companies, Inc. | T3 | No | $0 | IN |
| Anthem I PathWays Dual Care Advantage NFLOC (HMO D-SNP) | Anthem Insurance Companies, Inc. | T3 | No | $0 | IN |
| Wellpoint Full Dual Advantage (HMO-POS D-SNP) | Wellpoint Iowa, Inc. | T3 | No | $0 | IA |
| Wellpoint Full Dual Advantage 2 (HMO-POS D-SNP) | Wellpoint Iowa, Inc. | T3 | No | $0 | IA |
| Wellpoint Full Dual Advantage (HMO D-SNP) | Wellpoint West Virginia , Inc. | T3 | No | $0 | WV |
| Wellpoint Full Dual Advantage (HMO D-SNP) | Wellpoint Washington, Inc. | T3 | No | $0 | WA |
| Wellpoint Dual Advantage (HMO D-SNP) | Wellpoint Washington, Inc. | T3 | No | $0 | WA |
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is daridorexant 50 MG Oral Tablet [Quviviq] covered by Medicare Part D?
Yes, daridorexant 50 MG Oral Tablet [Quviviq] is covered by 960 Medicare Part D plans (19% of all Part D formularies).
What tier is daridorexant 50 MG Oral Tablet [Quviviq] on Medicare Part D plans?
daridorexant 50 MG Oral Tablet [Quviviq] averages Tier 3.5 across Part D plans, ranging from Tier 3 to Tier 4.
Does daridorexant 50 MG Oral Tablet [Quviviq] require prior authorization?
0% of Part D formularies require prior authorization for daridorexant 50 MG Oral Tablet [Quviviq]. Step therapy: 0%. Quantity limits: 100%.
How much does Medicare spend on daridorexant 50 MG Oral Tablet [Quviviq]?
In 2023, total Medicare Part D spending on daridorexant 50 MG Oral Tablet [Quviviq] was $16,342,719, covering 10,838 beneficiaries. The average spend per beneficiary was $1,507.91.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- lomustine 40 MG Oral Capsule T3.5
- 1 ML denosumab 60 MG/ML Prefilled Syringe [Prolia] T3.5
- tretinoin 0.001 MG/MG Topical Gel T3.5
- ethacrynic acid 25 MG Oral Tablet T3.5
- 24 HR canagliflozin 150 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [Invokamet] T3.5
- canagliflozin 150 MG / metformin hydrochloride 1000 MG Oral Tablet [Invokamet] T3.5